Highlights ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
6.03 ^USD	+3.34%		-8.08%	-59.50%

06-07	Transcript : ALX Oncology Holdings Inc. - Special Call
06-02	ALX Oncology Holdings Inc. Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 Aspen-07 Clinical Trial in Patients with Advanced Bladder Cancer	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ALX Oncology Holdings Inc. Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 Aspen-07 Clinical Trial in Patients with Advanced Bladder Cancer	06-02	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
ALX Oncology Holdings Inc. Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer	04-30	CI
ALX Oncology Reports Positive Data From Ongoing Phase 1/2 Trial of Evorpacept	04-10	MT
ALX Oncology Holdings Inc. Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (?R/R B-NHL?)	04-09	CI
North American Morning Briefing : Stock Futures -2-	03-11	DJ
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-07	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	03-07	CI
North American Morning Briefing : Investors Await -2-	12-11	DJ
ALX Oncology Reports Q3 Results With 'Sufficient' Funds to Finance Operations Into Early 2026	11-13	MT
ALX Oncology Q3 Net Loss Widens; Shares Ease After Hours	11-13	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
ALX Oncology Holdings Inc. Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer	23-10-03	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
ALX Oncology's Gastric Cancer Drug Receives European Commission's Orphan Drug Designation	23-06-26	MT
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Alx Oncology Announces Clinical Trial Collaboration with Sanofi to Evaluate Evorpacept in Combination with Sarclisa (Isatuximab-Irfc) in Patients with Multiple Myeloma	23-04-25	CI
ALX Oncology Holdings Inc. and Quantum Leap Healthcare Collaborative Announces First Patient Dosed in the I-SPY-P1 TRIAL in Breast Cancer	23-03-13	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
ALX Oncology Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights ALX Oncology Holdings Inc.

Equities

ALXO

US00166B1052

Highlights

Filters